Genomic profiling of tumor mutational burden enhances the predictive utility of immune checkpoint inhibitors such as PD-1/PD-L1 drugs, underscoring the significance of personalized approaches in cancer treatment [41]. This evidence concerns the gene CD274 and cancer.